Bu

(redirected from busulfan)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.

Bu

1. ISO 3166-1 alpha-2 code for Burma before it changed its name to Myanmar. This was the code used in international transactions to and from Burmese bank accounts.

2. ISO 3166-2 geocode for Burma. This was used as an international standard for shipping to Burma.

In both cases, the code is obsolete.
Mentioned in ?
References in periodicals archive ?
The patient had undergone chemotherapy with vincristine, doxorubicin, busulfan, and cyclophosphamide, and this had been followed by autologous peripheral stem cell transplantation.
Alkylating agents are the mustard gas derivatives such as Cyclophosphamide, and alkylsulfonates such as Busulfan.
A patent -protected, potent cytotoxic drug and intraveneous formulation of the alkylating agent busulfan.
Suspect Drugs Chemotherapy Agents Associated With Neurotoxicity Combination of methotrexate*, cyclophosphamide, and fluorouracil* Vinca alkaloids Cytarabine Platinum analogues Ifosfamide Taxol Taxotere Fludarabine Suramin Agents Associated With Occasional Reports of Cognitive or Motor Impairment L-asparagine Busulfan Hexamethylmelamine Procarbazine Thiotepa *Also associated with cognitive impairment individually.
1/2] of busulfan (y) Biliary excretion Serum protein Adult level (aa) Serum cholinesterase Serum arylesterase Alcohol 91 % - in vitro EA (ee) dehydrogenase Abbreviations: APAP, acetaminophen; BSP, bromosulfophthalein; CBZ, carbamazepine; CBZ-E, carbamazepine-epoxide; DMO, dimethadione; EA, enzyme activity; EH, epoxide hydrolase; GFR, glomerular filtration rate; PL, protein level; TMO, trimethadione.
Minnetonka, MN, worldwide rights to Busulfex Injection, an intravenous formulation of the alkylating agent busulfan, a drug often used in bone marrow transplantation.
In the study's earlier years, the first 12 children with sickle-cell disease received a bone marrow transplant plus busulfan and cyclophosphamide, two drugs known to facilitate transplants.
Busulfan is a preferred myeloablative agent for pediatric patients undergoing bone marrow transplantation and is both hepatically metabolized and hepatotoxic.
1,2] In another patient who developed cholesterol granulomas after busulfan treatment for chronic myeloid leukemia, it was postulated that the lesions were secondary to pneumocyte desquamation and independent of pulmonary hypertension.
The conditioning regimen for the transplant consisted of busulfan, cyclophosphamid, and antithymocyte globulin administered with a Hickman catheter.
Busulfan and other drugs cause discoloration of the skin, weakness, inability to eat and weight loss.
This test expands upon the group of chemotherapeutic TDM tests already offered by NMS Labs which includes Busulfan, Mercaptopurine, Mitotane, Platinum and Tamoxifen and metabolites.